Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This trial is designed to determine whether modifying the dose of isoniazid for individuals
according to their n-acetyltransferase 2 (NAT2) genotype could increase the probability of
achieving equivalence of area-under-the-curve.
Phase:
Phase 1
Details
Lead Sponsor:
Stanford University
Collaborators:
Federal University of Mato Grosso Fiocruz Mato Grosso do Sul National Institutes of Health (NIH)